A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065484 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2019001215 | DOI Listing |
Publication Analysis
Top Keywords
successful treatment
4
treatment thrombocytopenia
4
thrombocytopenia daratumumab
4
daratumumab allogeneic
4
allogeneic transplant
4
transplant case
4
case report
4
report literature
4
literature review
4
review source
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!